vs
MESA LABORATORIES INC（MLAB）与Velocity Financial, Inc.（VEL）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是Velocity Financial, Inc.的1.3倍（$65.1M vs $51.6M），Velocity Financial, Inc.净利率更高（67.3% vs 5.6%，领先61.8%），Velocity Financial, Inc.同比增速更快（32.8% vs 3.6%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $17.9M），过去两年Velocity Financial, Inc.的营收复合增速更高（32.3% vs 5.1%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
Velocity Financial, Inc.是一家总部位于美国的房地产金融企业，主要面向住宅投资物业提供专业化抵押贷款解决方案，与全美独立抵押贷款经纪人合作，为房地产投资者提供定制化的短期过桥贷款及长期租赁物业融资产品。
MLAB vs VEL — 直观对比
营收规模更大
MLAB
是对方的1.3倍
$51.6M
营收增速更快
VEL
高出29.2%
3.6%
净利率更高
VEL
高出61.8%
5.6%
自由现金流更多
MLAB
多$142.0K
$17.9M
两年增速更快
VEL
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $51.6M |
| 净利润 | $3.6M | $34.8M |
| 毛利率 | 64.2% | — |
| 营业利润率 | 12.2% | 97.0% |
| 净利率 | 5.6% | 67.3% |
| 营收同比 | 3.6% | 32.8% |
| 净利润同比 | 316.6% | 67.0% |
| 每股收益（稀释后） | $0.65 | $0.90 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABVEL
| Q4 25 | $65.1M | $51.6M | ||
| Q3 25 | $60.7M | $49.1M | ||
| Q2 25 | $59.5M | $47.6M | ||
| Q1 25 | $62.1M | $37.5M | ||
| Q4 24 | $62.8M | $38.9M | ||
| Q3 24 | $57.8M | $35.1M | ||
| Q2 24 | $58.2M | $32.4M | ||
| Q1 24 | $58.9M | $29.5M |
净利润MLABVEL
| Q4 25 | $3.6M | $34.8M | ||
| Q3 25 | $2.5M | $25.4M | ||
| Q2 25 | $4.7M | $26.0M | ||
| Q1 25 | $-7.1M | $18.9M | ||
| Q4 24 | $-1.7M | $20.8M | ||
| Q3 24 | $3.4M | $15.8M | ||
| Q2 24 | $3.4M | $14.8M | ||
| Q1 24 | $-254.6M | $17.3M |
毛利率MLABVEL
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | — | ||
| Q2 25 | 62.0% | — | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 64.0% | — | ||
| Q1 24 | 62.1% | — |
营业利润率MLABVEL
| Q4 25 | 12.2% | 97.0% | ||
| Q3 25 | 7.8% | 72.1% | ||
| Q2 25 | 5.1% | 71.3% | ||
| Q1 25 | 2.4% | 71.7% | ||
| Q4 24 | 9.2% | 82.5% | ||
| Q3 24 | 6.1% | 60.6% | ||
| Q2 24 | 9.6% | 61.3% | ||
| Q1 24 | -460.6% | 78.8% |
净利率MLABVEL
| Q4 25 | 5.6% | 67.3% | ||
| Q3 25 | 4.1% | 51.7% | ||
| Q2 25 | 8.0% | 54.6% | ||
| Q1 25 | -11.4% | 50.4% | ||
| Q4 24 | -2.7% | 53.5% | ||
| Q3 24 | 5.9% | 45.1% | ||
| Q2 24 | 5.8% | 45.6% | ||
| Q1 24 | -432.2% | 58.5% |
每股收益（稀释后）MLABVEL
| Q4 25 | $0.65 | $0.90 | ||
| Q3 25 | $0.45 | $0.65 | ||
| Q2 25 | $0.85 | $0.69 | ||
| Q1 25 | $-1.30 | $0.51 | ||
| Q4 24 | $-0.31 | $0.56 | ||
| Q3 24 | $0.63 | $0.44 | ||
| Q2 24 | $0.62 | $0.42 | ||
| Q1 24 | $-47.26 | $0.49 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $92.1M |
| 总债务越低越好 | $68.4M | — |
| 股东权益账面价值 | $186.7M | $672.5M |
| 总资产 | $434.8M | $7.4B |
| 负债/权益比越低杠杆越低 | 0.37× | — |
8季度趋势，按日历期对齐
现金及短期投资MLABVEL
| Q4 25 | $29.0M | $92.1M | ||
| Q3 25 | $20.4M | $99.0M | ||
| Q2 25 | $21.3M | $79.6M | ||
| Q1 25 | $27.3M | $51.7M | ||
| Q4 24 | $27.3M | $49.9M | ||
| Q3 24 | $24.3M | $44.1M | ||
| Q2 24 | $28.5M | $47.4M | ||
| Q1 24 | $28.2M | $34.8M |
总债务MLABVEL
| Q4 25 | $68.4M | — | ||
| Q3 25 | $69.4M | — | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | — | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
股东权益MLABVEL
| Q4 25 | $186.7M | $672.5M | ||
| Q3 25 | $178.5M | $634.3M | ||
| Q2 25 | $172.5M | $597.9M | ||
| Q1 25 | $159.8M | $563.2M | ||
| Q4 24 | $155.2M | $516.9M | ||
| Q3 24 | $161.5M | $484.6M | ||
| Q2 24 | $150.7M | $471.3M | ||
| Q1 24 | $145.4M | $452.9M |
总资产MLABVEL
| Q4 25 | $434.8M | $7.4B | ||
| Q3 25 | $430.4M | $7.0B | ||
| Q2 25 | $435.7M | $6.5B | ||
| Q1 25 | $433.3M | $6.0B | ||
| Q4 24 | $433.3M | $5.5B | ||
| Q3 24 | $454.1M | $5.2B | ||
| Q2 24 | $440.4M | $4.9B | ||
| Q1 24 | $446.8M | $4.6B |
负债/权益比MLABVEL
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $18.2M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $17.9M |
| 自由现金流率自由现金流/营收 | 27.7% | 34.6% |
| 资本支出强度资本支出/营收 | 1.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 5.17× | 0.52× |
| 过去12个月自由现金流最近4个季度 | $37.9M | $40.3M |
8季度趋势，按日历期对齐
经营现金流MLABVEL
| Q4 25 | $18.8M | $18.2M | ||
| Q3 25 | $8.2M | $11.5M | ||
| Q2 25 | $1.9M | $7.7M | ||
| Q1 25 | $12.7M | $3.5M | ||
| Q4 24 | $18.1M | $37.8M | ||
| Q3 24 | $5.3M | $-17.6M | ||
| Q2 24 | $10.7M | $11.5M | ||
| Q1 24 | $12.9M | $10.6M |
自由现金流MLABVEL
| Q4 25 | $18.0M | $17.9M | ||
| Q3 25 | $7.1M | $11.4M | ||
| Q2 25 | $884.0K | $7.6M | ||
| Q1 25 | $11.9M | $3.5M | ||
| Q4 24 | $17.3M | $37.5M | ||
| Q3 24 | $3.5M | $-17.6M | ||
| Q2 24 | $9.9M | $11.4M | ||
| Q1 24 | $12.3M | $10.5M |
自由现金流率MLABVEL
| Q4 25 | 27.7% | 34.6% | ||
| Q3 25 | 11.7% | 23.2% | ||
| Q2 25 | 1.5% | 15.9% | ||
| Q1 25 | 19.2% | 9.2% | ||
| Q4 24 | 27.6% | 96.4% | ||
| Q3 24 | 6.0% | -50.3% | ||
| Q2 24 | 16.9% | 35.1% | ||
| Q1 24 | 21.0% | 35.8% |
资本支出强度MLABVEL
| Q4 25 | 1.1% | 0.5% | ||
| Q3 25 | 1.8% | 0.1% | ||
| Q2 25 | 1.7% | 0.2% | ||
| Q1 25 | 1.2% | 0.2% | ||
| Q4 24 | 1.3% | 0.7% | ||
| Q3 24 | 3.1% | 0.2% | ||
| Q2 24 | 1.5% | 0.3% | ||
| Q1 24 | 0.9% | 0.1% |
现金转化率MLABVEL
| Q4 25 | 5.17× | 0.52× | ||
| Q3 25 | 3.32× | 0.45× | ||
| Q2 25 | 0.40× | 0.29× | ||
| Q1 25 | — | 0.19× | ||
| Q4 24 | — | 1.81× | ||
| Q3 24 | 1.54× | -1.11× | ||
| Q2 24 | 3.17× | 0.78× | ||
| Q1 24 | — | 0.61× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
VEL
| Related Party | $19.3M | 37% |
| Nonrelated Party | $16.9M | 33% |
| Other | $15.4M | 30% |
